{"id":"approved-covid-19-vaccine","safety":{"commonSideEffects":[{"rate":"null","effect":"Pain, redness, or swelling at the injection site"},{"rate":"null","effect":"Fatigue"},{"rate":"null","effect":"Headache"},{"rate":"null","effect":"Muscle pain"},{"rate":"null","effect":"Chills"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"The vaccine uses a piece of the virus's genetic material, specifically the spike protein, to stimulate the body's immune system to produce antibodies and immune cells that can recognize and fight the virus. This immune response helps protect against severe illness and death from COVID-19.","oneSentence":"This vaccine works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body build immunity against COVID-19.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:28:56.734Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of COVID-19 disease caused by SARS-CoV-2 virus"}]},"trialDetails":[{"nctId":"NCT06848309","phase":"","title":"Dissecting Human Immune Responses to Infection With Influenza or SARS-CoV-2","status":"RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-03-07","conditions":"Influenza, SARS-CoV-2 (COVID-19) Infection, Immune Response of Host","enrollment":300},{"nctId":"NCT03501576","phase":"","title":"Evaluation of Human Immune Responses Vaccination in Patients With Lymphoma","status":"RECRUITING","sponsor":"Emory University","startDate":"2018-04-06","conditions":"Chronic Lymphocytic Leukemia, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma","enrollment":200},{"nctId":"NCT04780659","phase":"PHASE4","title":"COVID-19 Vaccination of Immunodeficient Persons (COVAXID)","status":"COMPLETED","sponsor":"Karolinska University Hospital","startDate":"2021-02-23","conditions":"Covid19","enrollment":539},{"nctId":"NCT05436834","phase":"PHASE3","title":"A Study to Evaluate the Safety and Immunogenicity of the mRNA COVID-19 Vaccines in Healthy Children Between 6 Months to Less Than 6 Years of Age","status":"COMPLETED","sponsor":"ModernaTX, Inc.","startDate":"2022-06-21","conditions":"SARS-CoV-2","enrollment":1807},{"nctId":"NCT05032976","phase":"","title":"Korea Comirnaty Post-marketing Surveillance","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-03-18","conditions":"COVID-19, Vaccines, Adverse Effects","enrollment":12000},{"nctId":"NCT07215520","phase":"PHASE2","title":"Safety and Tolerability of a Newcastle Disease Virus-Based Mucosal COVID-19 Vaccine in Previously Vaccinated Adults","status":"RECRUITING","sponsor":"CastleVax Inc.","startDate":"2025-11-03","conditions":"COVID-19","enrollment":200},{"nctId":"NCT06672055","phase":"PHASE2","title":"A Study to Evaluate VXA-CoV2-3.3 COVID-19 Vaccine Against Currently Approved/Authorized mRNA COVID-19 Injectable Booster Vaccine in Adults Previously Immunized Against COVID-19 Infection","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vaxart","startDate":"2024-10-08","conditions":"SARS-CoV2, COVID-19","enrollment":10400},{"nctId":"NCT05556720","phase":"PHASE3","title":"Bringing Optimised COVID-19 Vaccine Schedules To ImmunoCompromised Populations (BOOST-IC): an Adaptive Randomised Controlled Clinical Trial","status":"ACTIVE_NOT_RECRUITING","sponsor":"Monash University","startDate":"2022-12-01","conditions":"HIV, Organ Transplantation, Lymphoma, Non-Hodgkin","enrollment":960},{"nctId":"NCT07134725","phase":"PHASE1, PHASE2","title":"Safety and Immunogenicity of a Chimeric Recombinant Covid19 Vaccine SpiN-Tec MCTI UFMG","status":"COMPLETED","sponsor":"Federal University of Minas Gerais","startDate":"2022-11-23","conditions":"COVID - 19","enrollment":432},{"nctId":"NCT04776317","phase":"PHASE1","title":"Chimpanzee Adenovirus and Self-Amplifying mRNA Prime-Boost Prophylactic Vaccines Against SARS-CoV-2 in Healthy Adults","status":"COMPLETED","sponsor":"National Institute of Allergy and Infectious Diseases (NIAID)","startDate":"2021-03-25","conditions":"COVID-19","enrollment":81},{"nctId":"NCT06761612","phase":"","title":"Retail COVID-19 Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Biomedical Advanced Research and Development Authority","startDate":"2024-10-19","conditions":"COVID - 19","enrollment":2660},{"nctId":"NCT05286242","phase":"","title":"Evaluating the Immune Response to COVID19 Vaccination in Immunodeficient Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Yale University","startDate":"2021-02-10","conditions":"Multiple Sclerosis, Autoimmune Blistering Disease, B-Cell Deficiency","enrollment":400},{"nctId":"NCT05181709","phase":"PHASE1","title":"A Live Recombinant Newcastle Disease Virus-vectored COVID-19 Vaccine Phase 1 Study.","status":"COMPLETED","sponsor":"Sean Liu","startDate":"2022-02-09","conditions":"SARS-CoV-2","enrollment":35},{"nctId":"NCT05605470","phase":"PHASE2","title":"Immunogenicity and Safety of ChulaCov19 BNA159 and ChulaCov19 BNA159.2 Vaccines as a Booster Dose in Adults","status":"COMPLETED","sponsor":"Technovalia, Pty Ltd","startDate":"2023-01-19","conditions":"COVID-19, SARS CoV 2 Infection","enrollment":150},{"nctId":"NCT05539482","phase":"NA","title":"Community-Based Health Education Programs for the Early Detection of, and Vaccination Against, COVID-19 and the Adoption of Self-Protective Measures of Hong Kong Residents","status":"RECRUITING","sponsor":"The Hong Kong Polytechnic University","startDate":"2022-11-01","conditions":"COVID-19","enrollment":1200},{"nctId":"NCT05470894","phase":"","title":"Liver Injury After COVID-19 Vaccination","status":"COMPLETED","sponsor":"Humanity & Health Medical Group Limited","startDate":"2022-09-05","conditions":"Subjects After COVID-19 Vaccination","enrollment":379},{"nctId":"NCT05370040","phase":"PHASE1, PHASE2","title":"THEMBA II T-Cell Vaccine: Vaccination With saRNA COVID-19 Vaccines","status":"TERMINATED","sponsor":"ImmunityBio, Inc.","startDate":"2022-05-05","conditions":"COVID-19","enrollment":60},{"nctId":"NCT04505722","phase":"PHASE3","title":"A Study of Ad26.COV2.S for the Prevention of SARS-CoV-2-Mediated COVID-19 in Adult Participants","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-09-07","conditions":"Participants With or Without Stable Co-morbidities Associated With Progression to Severe COVID-19 at Different Stages of the Protocol","enrollment":44325},{"nctId":"NCT04436276","phase":"PHASE1, PHASE2","title":"A Study of Ad26.COV2.S in Adults (COVID-19)","status":"COMPLETED","sponsor":"Janssen Vaccines & Prevention B.V.","startDate":"2020-07-15","conditions":"Covid-19 Prevention","enrollment":1085},{"nctId":"NCT04815031","phase":"","title":"Drug Use Investigation of COMIRNATY Intramuscular Injection","status":"COMPLETED","sponsor":"Pfizer","startDate":"2021-03-20","conditions":"COVID-19","enrollment":14570},{"nctId":"NCT06646744","phase":"","title":"Safety Study About the mRNA Vaccines Against COVID-19 in Children (PEDIVACOV-HCSC)","status":"COMPLETED","sponsor":"Ana Belen Rivas Paterna","startDate":"2022-03-08","conditions":"COVID-19 Vaccine Adverse Reaction","enrollment":2100},{"nctId":"NCT04348370","phase":"PHASE4","title":"BCG Vaccine for Health Care Workers as Defense Against COVID 19","status":"COMPLETED","sponsor":"Texas A&M University","startDate":"2020-04-20","conditions":"Coronavirus, Coronavirus Infection, Coronavirus as the Cause of Diseases Classified Elsewhere","enrollment":659},{"nctId":"NCT05743335","phase":"PHASE1","title":"A Phase 1 Study to Assess the Safety and Immunogenicity of JCXH-221, an MRNA-based Broadly Protective COVID-19 Vaccine","status":"COMPLETED","sponsor":"Immorna Biotherapeutics, Inc.","startDate":"2023-03-07","conditions":"COVID-19, Infectious Disease","enrollment":73},{"nctId":"NCT04973449","phase":"PHASE2, PHASE3","title":"Phase II/III Study of AZD2816, for the Prevention of COVID-19 in Adults","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2021-06-27","conditions":"COVID-19, SARS-CoV-2","enrollment":2843},{"nctId":"NCT06091410","phase":"PHASE4","title":"Immunogenicity of Concomitant Administration of COVID-19 Vaccines With Influenza Vaccines","status":"ACTIVE_NOT_RECRUITING","sponsor":"Catholic Kwandong University","startDate":"2023-09-25","conditions":"COVID-19, Influenza, Vaccine Reaction","enrollment":62},{"nctId":"NCT05775887","phase":"PHASE1","title":"A FIRST IN HUMAN TO EVALUATE THE SAFETY AND IMMUNOGENICITY OF SARS-CoV-2 UQSC2 VACCINE IN HEALTHY ADULTS.","status":"COMPLETED","sponsor":"The University of Queensland","startDate":"2023-05-08","conditions":"COVID-19","enrollment":70},{"nctId":"NCT05652543","phase":"PHASE2","title":"A PhaseⅡ Study to Evaluate the Safety & Immunogenicity of SARS-CoV-2 Alpha/Beta/Delta/Omicron Variants COVID-19 Vaccine","status":"COMPLETED","sponsor":"Sinocelltech Ltd.","startDate":"2023-01-05","conditions":"COVID-19 Pandemic","enrollment":518},{"nctId":"NCT04805125","phase":"PHASE3","title":"Immunocompromised Swiss Cohorts Based Trial Platform","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"2021-04-19","conditions":"Immunocompromised Patients","enrollment":610},{"nctId":"NCT04990466","phase":"PHASE2, PHASE3","title":"Phase 2b/3 Trial of VSV-ΔG SARS-CoV-2 Vaccine (BRILIFE) Against Approved Comparator Vaccine.","status":"WITHDRAWN","sponsor":"NeuroRx, Inc.","startDate":"2021-09-30","conditions":"COVID-19","enrollment":""},{"nctId":"NCT04776005","phase":"","title":"COVID-19 Vaccine Efficacy in Patients With Malignant Pathologies","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2021-01-22","conditions":"Solid Tumor, Hematologic Malignancy, Thoracic Cancer","enrollment":500},{"nctId":"NCT06168032","phase":"NA","title":"COVID-19 Vaccine Effectiveness Against Recurrent Infection Among Lung Cancer Patients and Biomarker Research","status":"RECRUITING","sponsor":"Peking Union Medical College Hospital","startDate":"2023-12-08","conditions":"COVID-19 Recurrent, Lung Cancer, Vaccination","enrollment":1224},{"nctId":"NCT05930730","phase":"PHASE2","title":"Immunogenicity and Safety of Comvigen (Bivalent) Vaccine","status":"UNKNOWN","sponsor":"Chulalongkorn University","startDate":"2023-10-09","conditions":"Safety of a Single Dose of COMVIGEN Vaccine, Reactogenicity of a Single Dose of COMVIGEN Vaccine, Immunogenicity of a Single Dose of COMVIGEN Vaccine","enrollment":450},{"nctId":"NCT05007860","phase":"","title":"Vaccine Responsiveness in Patients With Chronic Lymphocytic Leukemia","status":"COMPLETED","sponsor":"Massachusetts General Hospital","startDate":"2020-07-16","conditions":"Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma","enrollment":36},{"nctId":"NCT04998240","phase":"PHASE2","title":"Mix and Match Heterologous Prime-Boost Study Using Approved COVID-19 Vaccines","status":"UNKNOWN","sponsor":"International Vaccine Institute","startDate":"2021-12-29","conditions":"Covid19","enrollment":360},{"nctId":"NCT04910295","phase":"","title":"Immunogenicity and Safety of COVID-19 Vaccine in Cancer Patients","status":"COMPLETED","sponsor":"Seoul National University Hospital","startDate":"2021-03-26","conditions":"Cancer, Covid19","enrollment":112},{"nctId":"NCT04894682","phase":"","title":"Safety and Long-term Effects of COVID-19 Vaccines in Patients With Pulmonary Tumor","status":"WITHDRAWN","sponsor":"Guangdong Provincial People's Hospital","startDate":"2021-05-04","conditions":"Lung Cancer, Pulmonary Nodule, Solitary, Pulmonary Nodule, Multiple","enrollment":""},{"nctId":"NCT05228912","phase":"","title":"Immunization of 7 Different Vaccines Against SARS-COV-2 Across 4 Countries.","status":"COMPLETED","sponsor":"Hospital Clinica Nova","startDate":"2021-02-26","conditions":"Vaccine Adverse Reaction, COVID-19, Vaccine Reaction","enrollment":1870},{"nctId":"NCT05168709","phase":"PHASE4","title":"Investigating COVID-19 Vaccine Immunity in Children in the Melbourne Infant Study of BCG for Allergy and Infection Reduction","status":"COMPLETED","sponsor":"Murdoch Childrens Research Institute","startDate":"2022-01-20","conditions":"COVID-19, Vaccine Reaction, Immunization; Infection","enrollment":51},{"nctId":"NCT05268185","phase":"NA","title":"The BOOSTED (Booster Options Or Switching Tested for Effectiveness and Downsides Study) Trial (COVID-19)","status":"COMPLETED","sponsor":"University of California, San Francisco","startDate":"2022-01-18","conditions":"COVID-19, Vaccine Reaction, COVID-19 Pandemic","enrollment":301},{"nctId":"NCT04847596","phase":"","title":"A Multicenter Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2021-05-21","conditions":"Relapsing Multiple Sclerosis","enrollment":25},{"nctId":"NCT05208983","phase":"","title":"SafeTy and Efficacy of Preventative CoVID Vaccines","status":"UNKNOWN","sponsor":"University Health Network, Toronto","startDate":"2021-05-06","conditions":"COVID-19 Virus Infection, Vaccine Response","enrollment":1286},{"nctId":"NCT05009030","phase":"","title":"Anti-SARS-COV2 Vaccination Study in Lung Cancer Patients","status":"COMPLETED","sponsor":"Fundación GECP","startDate":"2021-05-06","conditions":"Lung Cancer, Covid19","enrollment":794},{"nctId":"NCT05471635","phase":"","title":"Variables Influencing Anti-COVID-19 Vaccinations Around the World: an Analysis Conducted on Aggregated Data Sourced From Institutional Databases to Understand Whether and How Different Variables Could Affect the Vaccine Coverage (WORLDCOV: Worldwide Determinants of COVID-19 Vaccination)","status":"UNKNOWN","sponsor":"Alberto Peano","startDate":"2022-06-20","conditions":"COVID-19 Vaccines","enrollment":205},{"nctId":"NCT05132855","phase":"PHASE1, PHASE2","title":"The Immune Response of Heterologous Boost Third Dose of mRNA and Protein COVID-19 Vaccine","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2021-11-30","conditions":"COVID-19, Breakthrough Infection","enrollment":340},{"nctId":"NCT04954651","phase":"","title":"Assessment of the Immunization Levels Against Sars-Cov2 Virus in Subjects Who Have Received EU-approved COVID-19 Vaccines","status":"COMPLETED","sponsor":"University of Patras","startDate":"2021-07-07","conditions":"SARS-CoV2 Infection, Vaccine Reaction","enrollment":1000},{"nctId":"NCT04750356","phase":"","title":"SARS-CoV-2 (COVID-19) Longitudinal Study: Understanding Susceptibility, Transmission and Disease Severity (Legacy Study)","status":"UNKNOWN","sponsor":"University College, London","startDate":"2021-01-27","conditions":"SARS-CoV Infection","enrollment":6000},{"nctId":"NCT05185817","phase":"PHASE2","title":"Effectiveness of COVID-19 Vaccine in Hematopoietic Stem Cell Transplant Patients","status":"UNKNOWN","sponsor":"Tehran University of Medical Sciences","startDate":"2021-11-01","conditions":"Hematopoietic Stem Cell Transplantation (HSCT), COVID-19 Vaccines, Immune System Tolerance","enrollment":100},{"nctId":"NCT04743388","phase":"","title":"Study of the Kinetics of Antibodies Against COVID-19 (SARS-CoV-2) and of Cellular Subpopulations of the Immune System","status":"UNKNOWN","sponsor":"National and Kapodistrian University of Athens","startDate":"2021-01-04","conditions":"COVID-19, Healthy Volunteers, Chronic Disease","enrollment":600},{"nctId":"NCT05095298","phase":"PHASE4","title":"Reactogenicity and Immunogenicity of Third Dose Vaccine Booster Following Two Doses of Inactivated Vaccines","status":"UNKNOWN","sponsor":"Huashan Hospital","startDate":"2021-08-01","conditions":"COVID-19","enrollment":400},{"nctId":"NCT05107479","phase":"NA","title":"Effectiveness of Interactive Voice Response for COVID-19 Vaccination Training in the Democratic Republic of the Congo","status":"COMPLETED","sponsor":"Stanford University","startDate":"2021-11-09","conditions":"COVID-19 Vaccine Knowledge, COVID-19 Vaccine Beliefs","enrollment":8959},{"nctId":"NCT04854876","phase":"NA","title":"Pilot Study to Evaluate the Safety, Tolerability, and Efficacy of 5-ALA-Phosphate + SFC as an Immune System Enhancer Along With Vaccination Against COVID-19","status":"WITHDRAWN","sponsor":"Royal College of Surgeons in Ireland - Medical University of Bahrain","startDate":"2021-08-15","conditions":"SARS-COV 2, Covid19","enrollment":""},{"nctId":"NCT04907331","phase":"PHASE2","title":"Heterologous SARS-CoV-2 Vaccination With ChAdOx-1 and BNT162b2","status":"UNKNOWN","sponsor":"Medical University Innsbruck","startDate":"2021-05-10","conditions":"SARS-CoV2 Infection","enrollment":3000},{"nctId":"NCT04813770","phase":"NA","title":"The Impact of Theory-based Messaging on Covid-19 Vaccination Intentions","status":"COMPLETED","sponsor":"University of Glasgow","startDate":"2021-04-06","conditions":"Vaccination, Covid19","enrollment":1113},{"nctId":"NCT04817657","phase":"","title":"Pre-approval Access for Janssen's COVID Vaccine VAC31518 for Treating Physician Use","status":"NO_LONGER_AVAILABLE","sponsor":"Janssen Research & Development, LLC","startDate":"","conditions":"Healthy","enrollment":""},{"nctId":"NCT04713163","phase":"","title":"COVID-19 Vaccine Induced Immunity","status":"UNKNOWN","sponsor":"University of Manitoba","startDate":"2021-01","conditions":"Covid19","enrollment":200},{"nctId":"NCT04686409","phase":"","title":"App-based Symptom Tracking After Corona Vaccination (CoCoV)","status":"UNKNOWN","sponsor":"University of Ulm","startDate":"2021-01-11","conditions":"Adverse Events in COVID-19 Vaccination","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":35,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Approved COVID-19 vaccine","genericName":"Approved COVID-19 vaccine","companyName":"Humanity & Health Medical Group Limited","companyId":"humanity-health-medical-group-limited","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine works by introducing a piece of genetic material from the SARS-CoV-2 virus to the body, which triggers an immune response and helps the body build immunity against COVID-19. Used for Prevention of COVID-19 disease caused by SARS-CoV-2 virus.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}